893750-76-0

Basic information

• Product Name: 3-Chloro-4-[3,4-dihydro-2(1H)-isoquinolinyl]-aniline
• Synonyms: 3-Chloro-4-[3,4-dihydro-2(1H)-isoquinolinyl]-aniline;3-CHLORO-4-(3,4-DIHYDROISOQUINOLIN-2(1H)-YL)ANILINE
• CAS NO: 893750-76-0
• Molecular Formula: C₁₅H₁₅ClN₂
• Molecular Weight: 258.75
• Mol File: 893750-76-0.mol

Chemical Properties

• Boiling Point: 462.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.257±0.06 g/cm3(Predicted)
• PKA: 5.75±0.40(Predicted)
• CAS DataBase Reference: 3-Chloro-4-[3,4-dihydro-2(1H)-isoquinolinyl]-aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Chloro-4-[3,4-dihydro-2(1H)-isoquinolinyl]-aniline(893750-76-0)
• EPA Substance Registry System: 3-Chloro-4-[3,4-dihydro-2(1H)-isoquinolinyl]-aniline(893750-76-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 893750-76-0(Hazardous Substances Data)

Upstream product

• 350-30-1 3-chloro-4-fluoronitrobenzene 
• 91-21-4 1,2,3,4-tetrahydroisoquinoline 
• 927703-87-5 2-(2-chloro-4-nitro-phenyl)-1,2,3,4-tetrahydro-isoquinoline 

Downstream Products

• 1238690-64-6 1-{[4-chloro-3-(3,4-dihydro-1H-isoquinolin-2-yl)-benzoylamino]-ethoxycarbonylimino-methyl}-1H-pyrazole-4-carboxylic acid ethyl ester 

Relevant articles and documents

Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 3. Engineering plasma stability by discovery and optimization of isoindolinone analogs

This Letter describes the further lead optimization of the VU0486321 series of mGlu1 positive allosteric modulators (PAMs), focused on addressing the recurrent issue of plasma instability of the phthalimide moiety. Here, we evaluated a number of phthalimide bioisosteres, and ultimately identified isoindolinones as the ideal replacement that effectively address plasma instability, while maintaining acceptable mGlu1 PAM potency, DMPK profile, CNS penetration and mGluR selectivity.

QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS

Quinazolinone compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.